Vol. 9, No. 1: JANUARY 2010 – EXECUTIVE SUMMARY
Welcome to the JANUARY 2010 issue of Pharma Marketing News. This is the Executive Summary version. See Article Summaries below.
Thank you for being a reader of Pharma Marketing News. To improve this service, I urge you to take the online Reader Feedback Survey and tell me your thoughts. I have already gotten some great ideas from readers!
Subscribe Now and get the current and future issues delivered FREE by e-mail every month!Also get DISCOUNTS ON SPECIAL SUPPLEMENTS!
Sincerely.
John Mack, Publisher & Editor
Pharma Marketing News
editor@news.pharma-mkting.com
Adobe Acrobat Reader is required to access articles.
Click here to obtain the latest version (it’s FREE!).
CONTENTS
- Up Front: Healthcare Communications vs. Pharma Marketing
- Predicting the Future of the Drug Industry
- Corporate Reputation in the New Media World
- Pharma Begins to Reveal Payments to Physicians
When Is It Acceptable for Pharma to Use Behavioral Targeting?
“The practice of advertising has clearly been revolutionized by the emergence of the Internet. Today, we can match the content of an ad to the interests of the consumer in ways undreamed of just a few short years ago,” said Nancy Hill, President & CEO, 4A’s.
Survey questions include:
- Have you ever used behavioral targeting in an online advertising campaign?
- Should the pharmaceutical industry adopt similar self-regulatory principles that were established by media and marketing trade associations to protect consumer privacy when employing behavioral targeting.
- Should pharma marketers use behavioral targeting at all?
- If they do use it, when is it appropriate?
Please take 2 minutes to answer this survey relating to the use of behavioral targeting to deliver ads online.
You will be able to see a summary of up-to-date de-identified results upon completion of the survey.
Your comments areconfidential (anonymous) unless you specifically provide your contactinformation at the end of the survey and allow us to attribute commentsto you personally.
Article Summaries
Up Front
Healthcare Communications vs. Pharma Marketing
Whenever someone refers to a pharmaceutical company as a “healthcarecompany” the hairs on the back of my neck (where I still have somehair) rise up. This often happens when I speak to agencies that doconsulting work for pharmaceutical companies and talk about “healthcarecommunications” when they actually mean pharmaceutical marketing.
Are pharmaceutical companies healthcare companies? Should we replace”pharmaceutical marketing” with “healthcare communications?”
Read on…this article is AVAILABLE NOW here:
www.news.pharma-mkting.com/PMNews_91_UpFront.pdf
Predicting the Future of the Drug Industry
What’s in Store for the Next Decade?
Every new year we either take a look back or ahead one year. Many people would rather forget about 2009 and look forward to better times in 2010. But what about looking even farther into the future? Since we just finished the first decade of the 21st century, why not look into our crystal balls to predict what the next decade (2010-2019) holds in store for the pharmaceutical industry.
Well, Pharma Marketing News did just that with its “Predicting the Future of the Drug Industry: 2010 & Beyond!” survey that was hosted online from 6 December 2009 through 8 January 2010. We collected over 100 responses and many interesting comments that are summarized in this article.
Topic headings include:
- Future Scenarios
- Summary of Results
- How ALL respondents voted on predictions
Subscribe Now and download this article FREE (offer ends February 19, 2010). Or pay-per-reprint without subscribing below: Order and pay for this reprint now using your credit card…
ONLY $6.95Download PDF file immediately after paying:
]]>
Corporate Reputation in the New Media World
Influencing the New Influencers
There is a direct link between corporate reputation and customer behavior, including recommending or prescribing your brand. In today’s negative environment beset by economic crisis and 24/7 communications, how can you enhance your reputation and ensure it delivers results?
In an online webinar entitled “Reputation Strategies That Drive Results: Turning Your Good Name into Good Business” Kantar Health explored the value of corporate reputation and corporate social responsibility from a traditional channel and digital media perspective and also from the view of understanding how this impacts the relationship between pharmaceutical and Key Opinion Leaders. This article summarizes the presentations made at that webinar.
Topic headings include:
- TRI*M Pharma Reputation Index
- Reputation Strategies in the New Influence Landscape
- Listening Platform Approach
- What to Measure
- The Social Media Elephant
- Strengthening Your Reputation with KOLs
- Attributes of Thought Leaders
- The Power of Peer Influence
- Social Media and KOLs
Subscribe Now and download this article FREE (offer ends February 19, 2010). Or pay-per-reprint without subscribing below: Order and pay for this reprint now using your credit card…
ONLY $9.95Download PDF file immediately after paying:
]]>
Pharma Begins to Reveal Payments to Physicians
Analyzing the Numbers to Spread the Sunshine
In January 2009, Senate Special Committee on Aging Chairman Herb Kohl (D-WI) and Senate Finance Committee Ranking Member Charles Grassley (R-IA) introduced the Physician Payments Sunshine Act of 2009. This act, which has been introduced in previous sessions of Congress, attempts to provide for transparency in the relationship between physicians and pharma companies with respect to payments and other transfers of value. Several states, including Massachusetts, Vermont, and Minnesota, have either passed or threaten to pass their own “sunshine” that forbid or put limits on gifts to physicians by pharma companies.
Typically, these laws require the public disclosure of types and amounts of payments made to physicians above a certain limit.In response, many pharmaceutical companies have voluntarily published or announced that they will publish a list of payments to physicians. Eli Lilly was the first pharma company to do, followed by Merck and GSK. Pfizer, Johnson & Johnson, and Medtronic have promised to do so in 2010.
This article reviews the lists published by Lilly, Merck, and GSK. The analysis gives us more insight into the fees paid by various companies, how the money was distributed by state and region in the US, and what types of activities (eg, speaker fees vs. consulting fees) physicians were paid to perform.
Topic headings include:
- No Standard Format
- Speaking vs. Consulting Fees
- Physician Payment Patterns
- State-by-State Analysis
- Regional Analysis
Subscribe Now and download this article FREE (offer ends February 19, 2010). Or pay-per-reprint without subscribing below: Order and pay for this reprint now using your credit card…
ONLY $4.95Download PDF file immediately after paying:
]]>
